Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future Distribution Date
ROCHESTER, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, has filed for the distribution of a special stock dividend of Impact Biomedical Inc.to DSS Inc. shareholders of record on July 10, 2023, pending SEC clearance. DSS shareholders of record as of 5:00 p.m. ET on July 10, 2023 (the “record date”) will be entitled to four (4) shares of Impact Biomedical Inc. for every one (1) share of DSS on the distribution date. The distribution date is to be determined.
The distribution is subject to the already filed S-1 being declared effective for registering the distribution. Shares will be registered under CUSIP Number 45259L 106. The record date is being changed due to distribution conditions and, as a result, will allow additional time for shareholder participation.
About Impact BioMedical Inc.
Impact BioMedical Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS. Impact BioMedical leverages its scientific expertise and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. Impact BioMedical is focused on a concerted effort in the research and discovery of promising products for the prevention, inhibition, and treatment of neurological, oncological, and immuno-related diseases. For more information on Impact BioMedical visithttp://impactbiomedinc.com/
About DSS, Inc.
DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Consumer Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. Corporate website: www.dssworld.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward- looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
Contact:
DSS Inc. Investor Relations
IR@dssworld.com
+1 (585) 565-2422
